Our Expertise
Oncology Focused Science Meets the Spirit of Exploration
Oncology-Focused Accelerating Therapeutic Possibilities
At the core of our focus, lies a deep understanding of the complexities that govern central mediators and internal pathways in the field of oncology. In the complex landscape of oncology, we are accelerating the development of product candidates in our pursuit of cutting-edge treatments. Guided by a commitment to expand what is therapeutically possible, our efforts are focused on breakthrough treatments for cancer and its related conditions.
​
FG-3246 – Fully Human Antibody-Drug Conjugate for Metastatic Castration-Resistant Prostate Cancer
​
FG-3246, our potential first-in-class fully human antibody-drug conjugate (ADC), demonstrates our ability to take a targeted and precision approach, aiming to address specific molecular pathways implicated in castrate-resistant prostate cancer. These therapeutic advancements underscore our multidimensional approach, combining molecular insights with strategic drug development to propel the field of oncology toward more personalized and effective treatments for individuals facing the challenges of cancer.
Roxadustat - HIF-PH Inhibitor for Myelodysplastic Syndromes
Simultaneously, our dedication to addressing cancer and cancer-related conditions is exemplified by our continued work to develop roxadustat in anemia associated with lower-risk myelodysplastic syndromes (“MDS”).
MDS are a diverse group of bone marrow disorders characterized by ineffective production of healthy blood cells and premature destruction of blood cells in the bone marrow, leading to anemia.
